Pharmaron Beijing Co., Ltd. (3759) disclosed that on October 28, 2025, it entered into agreements with various Biortus shareholders to acquire 82.54% of Biortus’s equity for approximately RMB1,346 million. Upon completion, Biortus is expected to become a subsidiary of Pharmaron Beijing.

Biortus focuses on providing Contract Research Organization services in structural biology for innovative drug research and development, noted for its expertise in cryo-electron microscopy (Cryo-EM) analysis. Pharmaron Beijing highlighted that combining Biortus’s structural biology capabilities with its existing bioscience services platform is anticipated to enhance technical offerings and strengthen early-stage R&D support for global clients.

According to disclosed financials, Biortus’s audited net profits after taxation reached RMB57.72 million for the year ended December 31, 2024, compared to RMB27.14 million for the prior year. As of September 30, 2025 (unaudited), Biortus’s net assets stood at RMB608.39 million. The transaction’s valuation considered Biortus’s historical financings, operating results, and comparable industry price-to-sales and price-to-earnings ratios.

Because certain selling parties are ultimately owned by a substantial shareholder and executive director of Pharmaron Beijing, the deal constitutes a connected transaction under Chapter 14A of the Listing Rules. The applicable percentage ratios exceed 0.1% but remain below 5%, requiring reporting and announcement but not independent shareholders’ approval. Pharmaron Beijing stated that the acquisition’s completion is subject to standard closing conditions, including due diligence results and necessary regulatory procedures. The company also noted that there is no certainty the transaction will proceed and advised investors to exercise caution.